Evolus Added to NASDAQ Biotechnology Index
The Nasdaq Biotechnology Index (NBI) is designed to track the performance of a set of NASDAQ-listed securities that meet certain eligibility criteria and are classified as either biotechnology or pharmaceuticals, according to the Industry Classification Benchmark (
Evolus is a company dedicated to aesthetic medicine focused on providing physicians and their patients with expanded choices in aesthetic treatments and procedures. Evolus’ lead candidate Jeuveau, also known by the chemical name prabotulinumtoxinA, is a 900 kDa purified botulinum toxin type A complex that was approved by Health Canada for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients under 65 years of age and is being evaluated for marketing approval in the United States and other areas.
Tel: +1 646-536-7028